Proteomic changes in serum of first onset, antidepressant drug-naïve major depression patients

International Journal of Neuropsychopharmacology

Volumn 17, Issue 10, 2014, Pages 1599-1608

  Stelzhammer, Viktoria ^a   Haenisch, Frieder ^a   Chan, Man K ^a   Cooper, Jason D ^a   Steiner, Johann ^b   Steeb, Hannah ^a   Martins de Souza, Daniel ^a,c,d   Rahmoune, Hassan ^a   Guest, Paul C ^a   Bahn, Sabine ^a,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical psychiatry; Inflammation; Major depressive disorder; Oxidative stress; Proteomics

Indexed keywords

ACUTE PHASE PROTEIN; ADVANCED GLYCATION END PRODUCT; BRAIN DERIVED NEUROTROPHIC FACTOR; CERULOPLASMIN; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COMPLEMENT COMPONENT C4B; COPPER ZINC SUPEROXIDE DISMUTASE; DIPEPTIDYL CARBOXYPEPTIDASE; FERRITIN; GROWTH HORMONE; HAPTOGLOBIN; HYDROCORTISONE; INTERLEUKIN 16; MACROPHAGE MIGRATION INHIBITION FACTOR; PLASMINOGEN; TRANSFERRIN; COMPLEMENT; CYTOKINE; PLASMA PROTEIN;

ADULT; AGE; ANTIDEPRESSANT DRUG NAIVE MAJOR DEPRESSION PATIENT; ARTICLE; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; EXPLORATORY RESEARCH; FEMALE; GENDER; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MAJOR DEPRESSION; MALE; MASS SPECTROMETRY; MENTAL PATIENT; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEOMICS; SMOKING; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PROCEDURES; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ADULT; ANALYSIS OF VARIANCE; BLOOD PROTEINS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; HYDROCORTISONE; IMMUNOASSAY; MALE; MASS SPECTROMETRY; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PROTEOMICS; PSYCHIATRIC STATUS RATING SCALES; STATISTICS AS TOPIC;

EID: 84930278700     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145714000819     Document Type: Article

References (44)

1. Alkhateeb AA, Connor JR (2013) The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta 1836:245-254.
2. Angelucci F, Aloe L, Jimenez-Vasquez P, Mathe AA (2002) Electroconvulsive stimuli alter the regional concentrations of nerve growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor in adult rat brain. J ECT 18:138-143.
3. Bartolomucci A, Leopardi R (2009) Stress and depression: preclinical research and clinical implications. PLoS ONE 4:e4265.
4. Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP, Mansfield BC (2008) Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17:2872-2881.
5. Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O (2001) Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64:43-51.
6. Breier A, Wolkowitz OM, Doran AR, Bellar S, Pickar D (1988) Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers. Psychiatry Res 25:187-194.
7. Brewis IA, Brennan P (2010) Proteomics technologies for the global identification and quantification of proteins. Adv Protein Chem Struct Biol 80:1-44.
8. Brunoni AR, Lopes M, Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11:1169-1180.
9. Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791-800.
10. Capuron L, Ravaud A, Dantzer R (2000) Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 18:2143-2151.
11. Charlton BG, Leake A, Wright C, Griffiths HW, Ferrier IN (1987) A combined study of cortisol, ACTH and dexamethasone concentrations in major depression. Multiple time-point sampling. Br J Psychiatry 150:791-796.
12. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton L, Merlo-Pich E, Alexander RC, Muglia P (2010) Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE 5:e9166.
13. Engelmann M, Landgraf R, Wotjak CT (2004) The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neuroendocrinol 25:132-149.
14. Fava M, Kendler KS (2000) Major depressive disorder. Neuron 28:335-341.
15. Gans RO (2006) The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am 90:573-591.
16. Herken H, Gurel A, Selek S, Armutcu F, Ozen ME, Bulut M, Kap O, Yumru M, Savas HA, Akyol O (2007) Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 38:247-252.
17. Huang TL, Lee CT (2007) Low serum albumin and high ferritin levels in chronic hemodialysis patients with major depression. Psychiatry Res 152:277-280.
18. Jaros JA, Guest PC, Bahn S, Martins-de-Souza D (2013) Affinity depletion of plasma and serum for mass spectrometry-based proteome analysis. Methods Mol Biol 1002:1-11.
19. Joyce PR, Hawes CR, Mulder RT, Sellman JD, Wilson DA, Boswell DR (1992) Elevated levels of acute phase plasma proteins in major depression. Biol Psychiatry 32:1035-1041.
20. Krishnamurthy D, Harris LW, Levin Y, Koutroukides TA, Rahmoune H, Pietsch S, Vanattou-Saifoudine N, Leweke FM, Guest PC, Bahn S (2013) Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects. World J Biol Psychiatry 14:478-489.
21. Levin Y, Jaros JA, Schwarz E, Bahn S (2010) Multidimensional protein fractionation of blood proteins coupled to data-independent nanoLC-MS/MS analysis. J Proteomics 73:689-695.
22. Li GZ, Vissers JP, Silva JC, Golick D, Gorenstein MV, Geromanos SJ (2009) Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics 9:1696-1719.
23. Lotrich FE (2009) Major depression during interferon-alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci 11:417-425.
24. Maes M (2011) Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 35:664-675.
25. Maes M, Meltzer HY, Buckley P, Bosmans E (1995) Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 244:325-329.
26. Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732-741.
27. Morera AL, Henry M, Garcia-Hernandez A, Fernandez-Lopez L (2007) Acute phase proteins as biological markers of negative psychopathology in paranoid schizophrenia. Actas Esp Psiquiatr 35:249-252.
28. Muller N (2010) COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 11:31-42.
29. Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arolt V, Muller N (2011) Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression - no influence of celecoxib treatment. J Affect Disord 134:217-225.
30. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W (1984) Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226:1342-1344.
31. Nielsen MJ, Petersen SV, Jacobsen C, Oxvig C, Rees D, Moller HJ, Moestrup SK (2006) Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein. Blood 108:2846-2849.
32. Raedler TJ (2011) Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 24:519-525.
33. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70:31-41.
34. RDC Team (2009) R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
35. Roy A, Pickar D, Paul S, Doran A, Chrousos GP, Gold PW (1987) CSF corticotropin-releasing hormone in depressed patients and normal control subjects. Am J Psychiatry 144:641-645.
36. Saab YB, Gard PR, Yeoman MS, Mfarrej B, El-Moalem H, Ingram MJ (2007) Renin-angiotensin-system gene polymorphisms and depression. Prog Neuropsychopharmacol Biol Psychiatry 31:1113-1118.
37. Schwarz E et al. (2010) Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 5:39-47.
38. Sen S, Duman R, Sanacora G (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64:527-532.
39. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK (2008) A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol 18:230-233.
40. Stelzhammer V, Rothermundt M, Guest PC, Michael N, Sondermann C, Kluge W, Martins-de-Souza D, Rahmoune H, Bahn S (2011) Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy. Proteomics Clin Appl 5:644-649.
41. Steptoe A, Ussher M (2006) Smoking, cortisol and nicotine. Int J Psychophysiol 59:228-235.
42. Wichers M, Maes M (2002) The psychoneuroimmunopathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 5:375-388.
43. Wolf TL, Kotun J, Meador-Woodruff JH (2006) Plasma copper, iron, ceruloplasmin and ferroxidase activity in schizophrenia. Schizophr Res 86:167-171.
44. Yarlagadda A, Alfson E, Clayton AH (2009) The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry (Edgmont) 6:18-22.